Eli Lilly and Co (LLY) reported quarterly earnings results on Tuesday, Jul-26-2016. The company said it had a profit of $0.86 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $0.85. The company posted revenue of $5404.80 million in the period, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .
Eli Lilly and Co opened for trading at $80.27 and hit $80.52 on the upside on Wednesday, eventually ending the session at $80.28, with a gain of 0.39% or 0.31 points. The heightened volatility saw the trading volume jump to 28,11,087 shares. Company has a market cap of $88,616 M.
Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.
In a different news, on Jun 13, 2016, Melissa S Barnes (Chief Eth/Cmpl Ofcr & SVP, ERM) sold 992 shares at $73.77 per share price. According to the SEC, on May 16, 2016, Jackson P Tai (director) purchased 1,080 shares at $75.75 per share price. On May 3, 2016, Donald A Zakrowski (Chief Accounting Officer) sold 1,600 shares at $75.99 per share price, according to the Form-4 filing with the securities and exchange commission.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.